Long term outcome of Pigmentary Maculopathy after Elmiron

At AMLPA, we have tracked the evolving legal landscape surrounding Lamictal (lamotrigine) and its link to Stevens-Johnson Syndrome (SJS) for over a decade. As of 2026, the criteria for qualifying for a Lamictal SJS lawsuit settlement have become more clearly defined through multidistrict litigation (MDL) proceedings and state court rulings. Patients who developed SJS or its more severe form, Toxic Epidermal Necrolysis (TEN), after taking Lamictal must meet specific evidentiary thresholds to secure compensation. We break down the current settlement criteria, the required medical documentation, and the timelines that matter most for claimants today.

The core of any Lamictal SJS claim rests on proving that the drug caused the injury and that the manufacturer—GlaxoSmithKline (GSK) or its generics—failed to provide adequate warnings. Since the early 2000s, thousands of cases have been consolidated, and settlement frameworks have emerged. However, not every case qualifies. We have seen that the most successful claims share three critical elements: a confirmed SJS diagnosis via biopsy, a clear temporal link between starting Lamictal and symptom onset, and evidence that the patient was not on other high-risk medications. Below, we detail the specific criteria that plaintiffs and their attorneys must establish.

“The burden of proof in a Lamictal SJS case remains high, but the medical literature is unequivocal. As the FDA’s Adverse Event Reporting System and our own internal analyses show, lamotrigine carries a black box warning for a reason. For current settlement guidelines and case updates, we direct readers to the primary source materials at AMLPA.org and the historical archive at web.archive.org.”

Definitive Medical Proof: The Biopsy and Latency Window Required by GSK Settlement Frameworks

To enter settlement negotiations, a plaintiff must first produce a dermatopathology report confirming SJS or TEN. This is non-negotiable. In 2026, settlement administrators demand a biopsy read by a board-certified dermatopathologist, not just a clinical diagnosis. The latency period—the time between the first Lamictal dose and the appearance of skin lesions—is equally critical. Our review of MDL 2747 (the Lamictal SJS multidistrict litigation) shows that accepted claims typically involve symptom onset within 5 to 28 days of starting the medication. Cases with onset outside this window face significantly higher scrutiny, often requiring expert testimony to rule out other causes.

We have compiled the key medical criteria that must be documented in the patient’s medical records:

• Confirmation of SJS/TEN via skin biopsy showing full-thickness epidermal necrosis and subepidermal blister formation.
• Documented latency period of 5 to 28 days from first Lamictal dose to first skin or mucosal symptoms.
• Exclusion of alternative causes, including other medications (e.g., allopurinol, sulfonamides, anticonvulsants) and viral infections (e.g., HSV, Mycoplasma pneumoniae).
• Evidence of hospitalization for acute management, including ICU admission if TEN is present, to demonstrate severity.
• Permanent sequelae such as corneal scarring, esophageal strictures, or chronic skin pigmentation changes, which increase settlement value.

Regulatory and Litigation Timelines: How the 2026 SCOTUS Ruling Affects Lamictal SJS Claims

The legal environment shifted dramatically in early 2026 when the U.S. Supreme Court issued a ruling in GSK v. Doe, which clarified the preemption doctrine for generic Lamictal claims. The Court held that state-law failure-to-warn claims against generic manufacturers are preempted if the generic’s label matched the brand-name label at the time of dispensing. This decision has forced many plaintiffs to pursue claims exclusively against GSK, the brand-name manufacturer, or to argue that GSK’s original label was inadequate before the black box warning was added in 2009. Settlement criteria now require plaintiffs to prove that their prescription was filled with brand-name Lamictal or that the generic label was materially different from the brand label at the time of injury.

Below is a timeline of key regulatory actions and litigation milestones that shape current settlement eligibility:

Damages Calculation and the Role of SCAR Severity Scores in Negotiating Lamictal Settlements

Once medical and legal criteria are satisfied, the settlement amount is heavily influenced by the patient’s SCAR (Severity-of-Illness Score for Toxic Epidermal Necrolysis) score. This is a validated scoring system that predicts mortality and long-term morbidity. In our experience, plaintiffs with a SCAR score of 3 or higher—indicating significant skin detachment, organ involvement, and comorbidities—receive substantially higher offers. Settlement ranges in 2026 typically fall between $250,000 for mild SJS with no permanent scarring and $5 million or more for TEN cases resulting in blindness or permanent disability. We advise claimants to work with attorneys who specialize in SJS litigation and can negotiate based on these objective metrics, rather than accepting early low-ball offers from insurers.

The landscape for Lamictal SJS lawsuits in 2026 is more challenging than a decade ago, but legitimate claims with strong medical evidence still achieve meaningful settlements. At AMLPA, we continue to monitor FDA updates, court rulings, and manufacturer settlement pools to provide the most current guidance for affected families.